Non-Small Cell Lung Cancer
🇺🇸 FDAFDA news and analysis for pharmaceutical BD, investment, and market access
Articles about Non-Small Cell Lung Cancer
Showing 1–12 of 26 articles
Quick answer
NovaPharmaNews Non-Small Cell Lung Cancer hub for FDA covers 26 published articles — news and analysis for pharma BD, investors, and market access teams. Browse related topics below or explore companies, pipeline, and events linked from each story.
EMA backs datopotamab deruxtecan, but lung cancer access remains unclear
EMA backs datopotamab deruxtecan for advanced lung cancer
FDA approves Keytruda for adjuvant NSCLC treatment, expanding Merck’s lung cancer label
FDA approves Merck’s Keytruda for adjuvant NSCLC treatment
FDA approves Keytruda for adjuvant NSCLC, a Merck catalyst
Lenacapavir PrEP shows high HIV-prevention efficacy in Gilead’s Phase 3 trials
Vertex launches Journavx after FDA approval for acute pain
AstraZeneca and Daiichi Sankyo datopotamab deruxtecan hits lung cancer endpoint
FDA approves Keytruda adjuvant NSCLC use in early-stage lung cancer
FDA approves Keytruda adjuvant NSCLC use: what Merck investors should watch
Novo Nordisk CagriSema Phase 3 Obesity Results Signal Key Catalyst
Listeria Outbreaks 2026: FDA and CDC Soft Cheese Recall Analysis for Pharma
Frequently asked questions
How often is this topic updated?
New articles are published continuously as regulatory, clinical, and commercial signals break. Use the content-type filters for latest news vs in-depth analysis.
Where does this coverage come from?
Editorial intelligence combines FDA openFDA, ClinicalTrials.gov, SEC EDGAR, congress calendars, and analyst reporting. See our data sources policy for attribution.